In a landmark decision announced at the European Congress of Endocrinology in Prague, the long-misunderstood condition known as polycystic ovary syndrome (PCOS) will now be referred to as polyendocrine metabolic ovarian syndrome (PMOS). This change, the result of over a decade of advocacy and research, aims to better represent the complexities of a disorder that affects approximately one in eight women globally.
A New Name for an Old Struggle
The renaming of PCOS to PMOS reflects a broader understanding of the condition, which impacts around 170 million women worldwide. The change was spearheaded by Professor Helena Teede from Melbourne’s Monash Centre for Health Research & Implementation, who emphasised that the previous term failed to encapsulate the multi-faceted nature of the disorder. “The term ‘polycystic’ misled patients and contributed to delays in diagnosis and care,” Teede stated, highlighting the need for a name that accurately portrays the hormonal imbalances and associated health risks that extend beyond reproductive issues.
The announcement marks the culmination of 14 years of consultation involving medical professionals and patient advocacy groups across six continents. The newly coined PMOS aims to shift focus from the reproductive system alone, acknowledging the disorder’s significant metabolic implications, including the risk of diabetes and cardiovascular disease.
Patient Perspectives Lead the Way
Maddy Mavrikis, a Sydney-based advocate and one of many women who shared her experience with the condition, expressed relief at the name change. Diagnosed with PCOS at 15, Mavrikis was initially told she might never conceive—a claim that later proved unfounded. “I never had cysts on my ovaries, which made the diagnosis confusing,” she noted, reflecting on her journey to understand the condition.
Mavrikis’s experience is echoed by countless others who have grappled with the misconceptions surrounding PCOS. The term itself has historically led to misdiagnoses and inadequate treatment, often reducing a complex hormonal disorder to a singular focus on ovarian health. Teede pointed out that many patients had long been advocating for a name that aligns with their experiences, asserting that “the voices of patients were instrumental in this change.”
The Call for Comprehensive Care
The implications of this name change stretch beyond mere semantics; they signal a potential shift in how medical professionals approach diagnosis and treatment. Historically, women with PCOS faced stigma and misunderstanding, often being told their condition was primarily a reproductive issue. This narrow focus has left many without the support they need to manage associated symptoms such as insulin resistance, weight gain, and mental health challenges.
Lorna Berry, a global advocate for PCOS awareness, emphasised the importance of including patient input in medical discourse. She noted that the new name is a significant step towards recognising PMOS as a complex endocrine disorder rather than a simple reproductive issue. “The process was robust, valuing patient voices in a way that is long overdue,” Berry said.
Towards Better Understanding and Treatment
With the name change poised to be fully integrated into international medical guidelines by 2028, there is hope that this shift will enhance awareness and lead to improved care for those living with PMOS. The change aims to foster a deeper understanding of the condition, encouraging healthcare providers to adopt a more holistic approach to treatment that includes lifestyle interventions alongside medical therapies.
Mavrikis, reflecting on her experiences, expressed cautious optimism: “Changing the name shows they are starting to pay attention. It could lead to better care and understanding for future generations.” The challenges faced by women with PMOS, including misdiagnosis and inadequate treatment, underscore the significance of this development.
Why it Matters
The renaming of PCOS to PMOS represents a critical acknowledgement of the complexities of this condition and the voices of those it affects. By embracing a terminology that reflects the hormonal and metabolic realities of the disorder, the medical community takes a significant step towards dismantling stigma and ensuring that women receive the comprehensive care they deserve. This change not only enhances understanding but also paves the way for better research, funding, and ultimately, improved health outcomes for millions of women worldwide.
